Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Price Target at $86.80

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been given an average rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $86.80.

Several equities analysts have issued reports on GPCR shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley began coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective on the stock. Finally, JMP Securities reduced their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GPCR. Bank of Montreal Can acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $1,064,000. Bellevue Group AG raised its holdings in shares of Structure Therapeutics by 2,858.7% in the first quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock worth $15,598,000 after acquiring an additional 351,626 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Structure Therapeutics in the second quarter valued at $1,178,000. abrdn plc boosted its stake in shares of Structure Therapeutics by 132.7% during the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after acquiring an additional 123,789 shares during the last quarter. Finally, First Light Asset Management LLC increased its position in Structure Therapeutics by 296.1% during the 2nd quarter. First Light Asset Management LLC now owns 590,647 shares of the company’s stock worth $23,195,000 after purchasing an additional 441,534 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $33.41 on Wednesday. The company has a market cap of $1.91 billion, a P/E ratio of -45.15 and a beta of -3.23. The firm has a fifty day moving average of $38.79 and a two-hundred day moving average of $39.55. Structure Therapeutics has a one year low of $26.61 and a one year high of $66.38.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.